Insight

State of the industry: It's different this time

State of the industry: It's different this time

The emergence of a cadre of profitable biotech companies is changing the traditional dynamic between big pharma, biotech and investors. How will the ecosystem continue to evolve?

The age of virtual pharma: Challenges and solutions for investor directors and successful boards

The age of virtual pharma: Challenges and solutions for investor directors and successful boards


Jan 20, 2016

The inability of pharma to absorb new assets through licensing and partnerships has not compromised future medicines development but has it inhibited further investment?

Bubble trouble? Have the biotech bulls had their run?

Bubble trouble? Have the biotech bulls had their run?


Jan 20, 2016

After posting its worst performance in 13 years in the third quarter, many are saying the biotech bull market has run its course. So what...

partnering360®: leverage and cultivate your dealmaker network

partnering360 is the network for dealmakers in the life science industry. This global community of more than 33,000 is constantly growing, and the partnering opportunities continually updating.